The observation that KSR1 expression was required for tumor-dependent ERK signaling, but not normal development, suggested the possibility that effectors of KSR1-dependent signaling pathways in tumor cells might reveal additional putative targets for cancer therapy that preferentially support tumor cell growth and viability. Here, KSR1 is linked to neoplasm.